Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
August 5, 2021 4:05 PM EDT
$6.6 million in net revenue for the second quarter 2021 (624% increase from first quarter 2021)
415 patient start forms (PSFs) received for LUPKYNIS during the second quarter (over a 60% increase from the first quarter 2021) and over 800 PSFs received year-to-date
Continued ex-U.S. execution highlighted by the submission of a voclosporin MAA to the EMA by Otsuka
Cash and cash equivalents, and investments of $323.7 million at June 30, 2021
Conference call to be hosted today at 4:30 p.m. EDT
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial... More
